Treatment adherence therapy in people with psychotic disorders: Randomised controlled trial

British Journal of Psychiatry

Volumn 197, Issue 6, 2010, Pages 448-455

  Staring, A B P ^a,b   Van Der Gaag, M ^c,d   Koopmans, G T ^e   Selten, J P ^f   Van Beveren, J M ^a   Hengeveld, M W ^a   Loonen, A J M ^g   Mulder, C L ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b BAVO Europoort   (Netherlands)

^c PARNASSIA PSYCHIATRIC INSTITUTE   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^f Rivierduinen Foundation   (Netherlands)

^g UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; PENFLURIDOL; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; BEHAVIOR THERAPY; BIPOLAR DISORDER; CATATONIC SCHIZOPHRENIA; CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DEPRESSIVE PSYCHOSIS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEBEPHRENIA; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MOTIVATION; OUTCOME ASSESSMENT; OUTPATIENT; PARANOID SCHIZOPHRENIA; PATIENT COMPLIANCE; QUALITY OF LIFE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT DURATION; UNDIFFERENTIATED SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HOSPITALIZATION; HUMANS; INTENTION TO TREAT ANALYSIS; INTERVIEW, PSYCHOLOGICAL; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MOTIVATION; MULTIVARIATE ANALYSIS; PATIENT EDUCATION AS TOPIC; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 78649728147     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.110.077289     Document Type: Article

References (40)

1. Keath SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003; 64: 1308-15.
2. Thomas P. The stable patient with schizophrenia-from antipsychotic effectiveness to adherence. Eur Neuropsychopharmacol 2007; 17 (suppl 2): s115-22. (Pubitemid 46320964)
3. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996; 57 (suppl 11): s53-60.
4. Fenton WS, Blyer C, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997; 23: 637-51.
5. Ucok A, Polat A, Cakir S, Genc A. One year outcome in first episode schizophrenia; predictors of relapse. Eur Arch Psychiatry Clin Neurosci 2006; 256: 37-43. (Pubitemid 43288242)
6. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California medicaid patients with schizophrenia. Psychiatr Serv 2004; 55: 886-91. (Pubitemid 39025215)
7. Hawton K, Sutton L, Haw C, Sinclair J, Deeks JJ. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry 2005; 187: 9-20. (Pubitemid 41002508)
8. Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002; 159: 1653-64.
9. Lincoln TM, Wilhelm K, Nestoriuc Y. Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: a meta-analysis. Schizophr Res 2007; 96: 2232-45. (Pubitemid 47500142)
10. Lecompte D, Pelc I. A cognitive-behavioral program to improve compliance with medication in patients with schizophrenia. Int J Ment Health 1996; 25: 51-6, (Pubitemid 126072977)
11. Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry 1998; 172: 413-9. (Pubitemid 28204550)
12. Maneesakorn S, Robson D, Gournay K, Gray R. An RCT of adherenve therapy for people with schizophrenia in Chiang Mai, Thailand. J Clin Nurs 2007; 16: 1302-12.
13. Gray R, Wykes T, Edmonds M, Leese M, Gournay K. Effect of a medication management training package for nurses on clinical outcomes for patients with schizophrenia. Cluster randomised controlled trial. Br J Psychiatry 2004; 185: 157-62. (Pubitemid 39061460)
14. O'Donnel C, Donohoe G, Sharkey L, Owens N, Migone M, Harries R, et al. Compliance therapy: a randomized controlled trial in schizophrenia. BMJ 2003; 327: 834-6. (Pubitemid 37271693)
15. Byerly MJ, Fisher R, Carmody T, Rush AJ. A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2005; 66: 997-1001. (Pubitemid 41191791)
16. Gray R, Leese M, Bindman J, Becker T, Burti L, David A, et al. Adherence therapy for people with schizophrenia. European multicenter randomised controlled trial. Br J Psychiatry 2006; 189: 508-14. (Pubitemid 44876869)
17. National Institute for Health and Clinical Excellence (NICE). Schizophrenia; Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update). NICE, 2009 (http://www.nice.org.uk/nicemedia/pdf/CG82FullGuideline.pdf).
18. Staring ABP, Mulder CL, Van der Gaag M, Selten JP, Loonen AJM, Hengeveld MW. Understanding and improving treatment adherence in patients with psychotic disorders; a review and a proposed intervention. Curr Psychiatry Rev 2006; 2: 487-94.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). APA, 1994.
20. Tait L, Birchwood M, Trower P. A new scale (SES) to measure engagement with community mental health services. J Ment Health 2002; 11: 191-8. (Pubitemid 34496793)
21. World Health Organization. Composite International Diagnostic Interview (version 2.1 Auto). WHO, 1997.
22. Kikkert MJ, Dekker JJM, Koeter MWJ, Schene AH. The Inventory of Medication Intake (IMI): validation of an instrument for assessing adherence to antipsychotic medication. In Medication Adherence in Patients with Schizophrenia (ed MJ Kikkert): 113-32. Dissertation at the University of Amsterdam, 2010.
23. Wing JK, Beevor AS, Curtis RH, Park SB, Hadden S, Burns A. Health of the Nation Outcome Scales (HoNOS). Research and development. Br J Psychiatry 1998; 172: 11-8. (Pubitemid 28122520)
24. Kikkert MJ, Barbui C, Koeter MWJ, David AS, Leese M, Tansella M, et al. Assessment of medication adherence in patients with schizophrenia. The achilles heel of adherence research. J Nerv Men Dis 2008; 196: 274-81. (Pubitemid 351548727)
25. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76.
26. Staring ABP, Mulder CL, Duivenvoorden HJ, De Haan L, Van der Gaag M. Fewer symptoms vs. more side-effects in schizophrenia? Opposing pathways between entipsychotic medication compliance and quality of life. Schizophr Res 2009; 113: 27-33.
27. Prieto L, Sacristán JA, Hormaechea JA, Casado A, Badía X, Gómez JC. Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr Med Res Opin 2003; 20: 827-35.
28. Lamers LM, Stalmeier PFM, McDonnell J, Krabbe PFM, Van Busschbach JJ. Measuring the quality of life in cost-utility analyses: the Dutch EQ-5D tariff. Ned Tijdschr Geneeskd 2005; 149: 1574-8.
29. Birchwood M, Smith J, Drury V, Healy J, Macmillan F, Slade M. A self-report insight scale for psychosis: reliability, validity, and sensitivity to change. Acta Psychiatr Scand 1994; 89: 62-7.
30. Drayton M, Birchwood M, Trower P. Early attachment experience and recovery from psychosis. Br J Psychol 1998; 37: 269-84.
31. Link B, Struening EL, Neese-Todd S, Asmussen S, Phelan JC. On describing and seeking to change the experience of stigma. Psychiatr Rehabil Skills 2002; 6: 201-31.
32. Horvath AO, Greenberg LS. Development and validation of the working alliance inventory. J Consult Psychol 1989; 36: 223-33.
33. Cohen J. Statistical Power Analysis for the Behavioral Sciences (2nd edn). Lawrence Erlbaum Associates, 1988.
34. O'Donoghue B, Lyne J, Hill M, Larkin C, Feeney L, O'Callaghan E. Involuntary admission from the patient's perspective. Soc Psychiatry Psychiatr Epidemiol 2010; 45: 631-8.
35. Valenstein M, Kavanagh J, Lee T, Reilly P, Dalack GW, Grabowski J, et al. Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness. Schizophr Bull 2009; Nov 21 (Epub ahead of print).
36. Hewitt J, Coffey M. Therapeutic working relationship with people with schizophrenia: literature review. J Adv Nurs 2005; 52: 561-70.
37. Staring ABP, Van der Gaag M, Van den Berge M, Duivenvoorden HJ, Mulder CL. Stigma moderates the associations of insight with depressed mood, low self-esteem, and low quality of life in patients with schizophrenia spectrum disorders. Schizophr Res 2009; 115: 363-9.
38. Rathod S, Kingdon D, Smith P, Turkington D. Insight into schizophrenia: the effects of cognitive behavioural therapy on the components of insight and association with sociodemographics - data on a previously published randomised controlled trial. Schizophr Res 2005; 74: 211-9.
39. Claassen D, Fakhoury WK, Ford R, Priebe S. Money for medication: financial incentives to improve medication adherence in assertive outreach. Psychiatr Bull 2007; 31: 4-7.
40. Patel MX, David AS. Medication adherence: predictive factors and enhancement strategies. Psychiatry 2007; 6: 357-61.